Browsing by Author "Painuli, Sakshi"

Now showing 1 - 3 of 3

Artemisia spp.: An Update on Its Chemical Composition, Pharmacological and Toxicological Profiles
(Hindawi Publishing Corporation, 2022-09) Sharifi-Rad, Javad; Herrera-Bravo, Jesús; Semwal, Prabhakar; Painuli, Sakshi; Badoni, Himani; Ezzat, Shahira M; Farid, Mai M; Merghany, Rana M; Aborehab, Nora M; Salem, Mohamed A; Sen, Surjit; Acharya, Krishnendu; Lapava, Natallia; Martorell, Miquel; Tynybekov, Bekzat; Calina, Daniela; Cho, William C
Artemisia plants are traditional and ethnopharmacologically used to treat several diseases and in addition in food, spices, and beverages. The genus is widely distributed in all continents except the Antarctica, and traditional medicine has been used as antimalarial, antioxidant, anticancer, antinociceptive, anti-inflammatory, and antiviral agents. This review is aimed at systematizing scientific data on the geographical distribution, chemical composition, and pharmacological and toxicological profiles of the Artemisia genus. Data from the literature on Artemisia plants were taken using electronic databases such as PubMed/MEDLINE, Scopus, and Web of Science. Selected papers for this updated study included data about phytochemicals, preclinical pharmacological experimental studies with molecular mechanisms included, clinical studies, and toxicological and safety data. In addition, ancient texts and books were consulted. The essential oils and phytochemicals of the Artemisia genus have reported important biological activities, among them the artemisinin, a sesquiterpene lactone, with antimalarial activity. Artemisia absinthium L. is one of the most famous Artemisia spp. due to its use in the production of the absinthe drink which is restricted in most countries because of neurotoxicity. The analyzed studies confirmed that Artemisia plants have many traditional and pharmacological applications. However, scientific data are limited to clinical and toxicological research. Therefore, further research is needed on these aspects to understand the full therapeutic potential and molecular pharmacological mechanisms of this medicinal species.
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer’s Disease
(Bentham Science Publishers B.V., 2023-03) Painuli, Sakshi; Semwal, Prabhakar; Zam, Wissam; Taheri, Yasaman; Ezzat, Shahira M; Zuo, Peijun; Li, Liping; Kumar, Dileep; Sharifi-Rad, Javad; Cruz-Martins, Natália
Alzheimer’s disease (AD) is an increasingly common neurodegenerative disease that at- tracts the attention of researchers and medical community in order to develop new, safe and more effective drugs. Currently available drugs could only slow the AD progression and relieve the symptoms, in addition to being linked to moderate-to-severe side effects. N-methyl D-aspartate (NMDA) receptors antagonists were reported to have the ability to block the glutamate-mediated excitotoxic activity being good therapeutic targets for several neurodegenerative diseases, includ- ing AD. Based on data obtained so far, this review provides an overview over the use of NMDA antagonists for AD treatment, starting with a key emphasis on present features and future aspects regarding the use of NMDA antagonists for AD, and lastly a key focus is also given on its use in precision medicine.
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer Disease
(Bentham Science Publishers, 2022-04) Painuli, Sakshi; Semwal, Prabhakar; Zam, Wissam; Taheri, Yasaman; Ezzat, Shahira M; Zuo, Peijun; Li, Liping; Kumar, Dileep; Sharifi-Rad, Javad; Cruz- Martins, Natália
Alzheimer disease (AD) is an increasingly common neurodegenerative disease, and therefore researchers and medical community are devoting a key attention in searching new, safer and more effective drugs than the currently available ones. Currently available drugs are not an effective treatment to the disease, they only slow the AD progression and act in symptoms relief, despite being linked to moderate-to-severe side effects. N-methyl D-aspartate (NMDA) receptors antagonists and cholinesterase inhibitors, and combination therapy, are the most often used therapeutic regimens in AD patients. In particular, NMDA receptors have being target of an increasing attention while good therapeutic targets for several neurodegenerative diseases, including AD, due to their ability to block the glutamate-mediated excitotoxic activity. Based on data obtained so far, this review provides an overview on the use of NMDA antagonists for AD treatment, starting with a key emphasis on present features and future aspects on the use of NMDA antagonists for AD, and lastly a key focus is also given on its use for precision medicine.